Business Wire

ITEN

21.11.2023 07:24:28 CET | Business Wire | Press release

Share
ITEN Named as CES 2024 Best of Innovation Awards Honoree

I-TEN,SA today announced that it has been named a CES® 2024 Best of Innovation Awards Honoree for its 250µA.h micro-battery This year’s CES Innovation Awards program received a record number of over 3000 submissions. The announcement was made ahead of CES 2024, the world’s most powerful technology event, happening Jan. 9-12 in Las Vegas, NV.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120706085/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Solid-state SMD Micro-battery (Photo: I-TEN SA)

The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in 29 consumer technology product categories. Those with the highest rating receive the “Best of Innovation” distinction. An elite panel of industry expert judges, including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetic and design.

ITEN are a French company manufacturing solid-state SMD micro-batteries. As a fully integrated device manufacturer, ITEN control the complete value chain from material synthesis up to the packaging and test. ITEN have raised more than 120M$ since the foundation of the company and their technology has been granted more than 300 patents worldwide so far.

The new 250µA.h micro-batteries have a footprint of #4,5 x 3,2 mm and have two more main features:
- they can be recharged quickly (80% in 8 minutes) and simply at constant voltage (like a capacitor);
- they can deliver high power and high peak currents, of more than 30mA over 100ms, meaning a C-Rate of more than 120.

The C-rate is a key performance for batteries used in low power IOT solutions. Such low-power IOT solutions do indeed consume less and less energy on the average but from time-to-time, the power supply must deliver current spikes to power RF transceivers, microcontrollers sensors or actuators for instance.

Thanks to the high C-rates of ITEN’s batteries, it is now possible to reduce the size and the capacity (by a factor up to 500 or 1000) of the batteries to be used in such IOT solutions: This also reduces the carbon footprint of the energy storage solutions by a factor at least 200 compared to coin cells and this even makes it possible to design ecofriendly autonomous solutions by combining energy harvesting solutions and a micro-battery of very small capacity. In addition, ITEN micro-batteries are ROHS and REACH compliant and contain neither toxic materials, nor heavy metals, nor solvents, no rare earths and do not require a specific recycling process at the end of the system life.

They are thus a concrete response to electronics designers looking for ecofriendly alternatives to coin cells. In this respect, ITEN solutions fit in with the European Directive recommending getting rid of non-rechargeable batteries in all electronic system designs from year 2030.

“We are thrilled and honored by this Best of Innovation Award at CES 2024. This recognizes our disruptive solid-state batteries as main contributors to sustainability, eco-design and smart energy solutions” stated Fabien Gaben, Chairman of the board and founder of the company. “This is really a breakthrough in the way of powering autonomous embedded systems.”

The CES 2024 Innovation Awards honorees, can be found at CES.tech/innovation. More will be revealed in January during CES Unveiled.

About ITEN:
ITEN is the leading company developing and manufacturing ecofriendly solid-state lithium-ion SMD micro batteries. Such micro batteries are rechargeable In a few minutes and can deliver power over a wide operating temperature range. They are used in many applications as back-up power supply, or to assist primary cells in delivering power or to power autonomous sensor nodes, tracking and monitoring solutions, sensor data loggers, beacons and RF tags, smartphone peripherals, medical devices, home and building automation, smart cities, wearables, and e-textiles.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231120706085/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye